Court Case Highlights Shareholder Dilution in Capital Raises

A legal dispute currently before the Tel Aviv District Court centers on allegations of shareholder oppression during a capital raise for the company Genwise. Leon Peretz, one of the company's founders, claims that a funding round in early 2025 significantly diluted his holdings and control, as it was conducted at a valuation reflecting a 95% decrease from the previous round. The defendants argue that the company faced imminent closure and urgently needed capital, and that all shareholders were offered the opportunity to participate in the new round.

This case illustrates the complex issue of capital raises, which can be essential for a company's survival but can also drastically alter ownership structures if certain shareholders do not participate. Israeli corporate law, specifically Section 191 of the Companies Law, allows courts to intervene in cases of shareholder oppression. However, courts generally do not consider a "down round", a funding round at a lower valuation than previous ones, as inherently oppressive. The key factor is not merely the dilution of a shareholder's stake, but the reasons behind the capital raise, the price, the decision-making process, and the actual impact on the company and its shareholders.

To succeed in a claim of oppression, a shareholder must present evidence suggesting the capital raise was not conducted in good faith or for the company's benefit, and that the share price does not reflect fair value. If such evidence is shown, the burden may shift to the company to prove the raise was justified. This involves demonstrating that the company's needs were assessed, alternative financing options were explored, and negotiations were conducted to secure the best possible terms. A well-documented process, even during a financial crisis, is crucial for the company to defend its decisions.

While a genuine need for funding can justify difficult capital raise terms and significant shareholder dilution, it does not absolve the company and its board from explaining the chosen valuation, deal structure, and investor identity. The ultimate test is whether the process was fair given the company's business needs and the impact on all shareholders, not simply whether dilution occurred. Even pre-agreed dilution mechanisms in shareholder agreements must be exercised in good faith and align with the company's genuine needs and appropriate valuation methodologies.